An observational study in Hypertension, sponsored by AstraZeneca. Completed at 8 sites in Serbia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-10.
Sponsored by AstraZeneca · Observational
This study is aimed to evaluate response rate of the antihypertensive treatment with a calcium antagonist in real life practice, to evaluate patients' quality of life and to collect the following Serbia-specific epidemiology data on hypertension: demographic data, patents characteristics, and patients' management/treatment.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 300 is above the median of 210 across 1,359 observational studies indexed under Hypertension.
Browse Hypertension studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Speciality care clinics
Inclusion Criteria:
Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist
To evaluate proportion of patients on antihypertensive pharmacological treatment reaching SBP goals according to the ESC 2007 guidelines (<140 mmHg*).
Time frame: 24 weeks
To evaluate proportion of patients on antihypertensive pharmacological treatment reaching DBP goals according to the ESC 2007 guidelines (<90 mmHg*).
Time frame: 24 weeks
To collect local epidemiological date on patients with hypertension (demographic data; hypertension management data: treatment, treatment changes and tolerability data).
Time frame: 24 weeks
To evaluate patients quality of life after 12 and 24 weeks by using patients quality of life questionnaire
Time frame: 24 weeks
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca